C.E.O. & Chief Cardiac Surgeon, National Heart Institute, 49-50 Community Centre, East of Kailash, New Delhi, 110065, India.
Indian Heart J. 2021 Mar-Apr;73(2):242-243. doi: 10.1016/j.ihj.2021.01.019. Epub 2021 Jan 29.
Despite no incontrovertible data, Digoxin use has been demonised. As a consequence, a lot of patients, stable on Digoxin, have been taken off it and offered alternative drugs. However, there is some light at the end of the tunnel for Digoxin, with the reporting of RATE-AF Trial at the recent European Society of Cardiology Congress. Compared to Bisoprolol, Digoxin use was associated with statistically significantly greater improvements in symptomatology and NT ProBNP levels making Digoxin a first line drug for rate control in permanent AF.
尽管没有确凿的数据，但地高辛的使用已被妖魔化。结果，许多服用地高辛的稳定患者已被停药并改用其他药物。然而，地高辛在隧道尽头出现了一线曙光，最近在欧洲心脏病学会大会上报告了 RATE-AF 试验。与比索洛尔相比，地高辛的使用与症状和 NT ProBNP 水平的统计学显著改善相关，使地高辛成为永久性房颤患者的一线控制心率药物。
